High-intensity focused ultrasound: where are we and where to from here?

References

• Heidenreich A, Aus G, Bolla M et al. [EAU guidelines on prostate cancer]. Actas Urol. Esp.33(2), 113–126 (2009).
   PubMedGoogle Scholar
• National Institute for Clinical Excellence. Prostate Cancer Diagnosis and Treatment. (CG 58). National Collaborating Centre for Cancer, Cardiff, UK (2008).
   Google Scholar
• Lynn JG, Zwemer RL, Chick AJ, Miller AE. A new method for the generation and use of focused ultrasound in experimental biology. J. Gen. Phys.26,179–193 (1942).
   PubMedGoogle Scholar
• Fry WJ, Mosberg WH Jr, Barnard JW, Fry FJ. Production of focal destructive lesions in the central nervous system with ultrasound. J. Neurosurg.11(5), 471–478 (1954).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res.55(15), 3346–3351 (1995).
   PubMed Web of Science ®Google Scholar
• Gelet A, Chapelon JY, Margonari J et al. Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J. Endourol.7(3), 249–253 (1993).
   PubMed Web of Science ®Google Scholar
• Gelet A, Chapelon JY, Margonari J et al. High-intensity focused ultrasound experimentation on human benign prostatic hypertrophy. Eur. Urol.23(Suppl. 1), 44–47 (1993).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Kratzik C, Susani M, Marberger M. Tissue ablation in benign prostatic hyperplasia with high intensity focused ultrasound. J. Urol.152(6 Pt 1), 1956–1960 (1994).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Kratzik C, Szabo N, Susani M, Vingers L, Marberger M. Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur. Urol.23(Suppl. 1), 39–43 (1993).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Marberger M. Tissue ablation by high-intensity focused ultrasound in benign prostatic hypertrophy. J. Urol. (Paris)99(6), 349 (1993).
   Google Scholar
• Colombel M, Gelet A. Principles and results of high-intensity focused ultrasound for localized prostate cancer. Prostate Cancer Prostatic Dis.7(4), 289–294 (2004).
   PubMed Web of Science ®Google Scholar
• Beerlage HP, van Leenders GJ, Oosterhof GO et al. High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate39(1), 41–46 (1999).
   PubMed Web of Science ®Google Scholar
• Chaussy C, Thuroff S, Rebillard X, Gelet A. Technology insight: high-intensity focused ultrasound for urologic cancers. Nat. Clin. Pract. Urol.2(4), 191–198 (2005).
   PubMedGoogle Scholar
• Uchida T, Sanghvi NT, Gardner TA et al. Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2N0M0 localized prostate cancer: a preliminary report. Urology59(3), 394–398 (2002).
   PubMed Web of Science ®Google Scholar
• Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur. Urol.40(2), 124–129 (2001).
   PubMed Web of Science ®Google Scholar
• Rebillard X, Soulie M, Chartier-Kastler E et al. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int.101(10), 1205–1213 (2008).
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. High Intensity Focused Ultrasound for Prostate Cancer (IPG 118). NICE, London, UK (2005).
   Google Scholar
• Lukka H, Waldron T, Chin J et al. High Intensity Focused Ultrasound for Prostate Cancer: Guideline Reccomendations. Cancer Care Ontario, ON, Canada (2009).
   Google Scholar
• Uchida T, Nakano M, Shoji S et al. Ten year biochemical disease free survival after high intensity focused ultrasound (HIFU) for localised prostate cancer: comparison with three different generation devices. J. Urol.181(4), 228 (2009).
   Web of Science ®Google Scholar
• Ahmed HU, Zacharakis E, Dudderidge T et al. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br. J. Cancer101(1), 19–26 (2009).
   PubMed Web of Science ®Google Scholar
• Blana A, Brown SC, Chaussy C et al. Primary prostate HIFU without pretreatment hormone therapy: biochemical survival of 468 patients tracked with the @-registry. J. Urol.181(4), 227 (2009).
   Web of Science ®Google Scholar
• Mearini L, D’Urso L, Collura D et al. Visually directed transrectal high intensity focused ultrasound for the treatment of prostate cancer: a preliminary report on the Italian experience. J. Urol.181(1), 105–111 (2009).
   PubMed Web of Science ®Google Scholar
• Blana A, Murat FJ, Walter B et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur. Urol.53(6), 1194–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Blana A, Rogenhofer S, Ganzer R et al. Eight years’ experience with high-intensity focused ultrasonography for treatment of localized prostate cancer. Urology.72(6), 1329–1333 (2008).
   PubMed Web of Science ®Google Scholar
• Misrai V, Roupret M, Chartier-Kastler E et al. Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer. World J. Urol.26(5), 481–485 (2008).
   PubMed Web of Science ®Google Scholar
• Ganzer R, Rogenhofer S, Walter B et al. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur. Urol.53(3), 547–553 (2008).
   PubMed Web of Science ®Google Scholar
• Blana A, Murat FJ, Walter B et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur. Urol.53(6), 1194–1201 (2007).
   Google Scholar
• Chaussy C, Thuroff S, Knauer K. Ten years of high intensity focused ultrasound (HIFU) in prostate cancer (PCA). Eur. Urol. Suppl.5(2), 133 (2006).
   Google Scholar
• Poissonnier L, Chapelon JY, Rouviere O et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur. Urol.51(2), 381–387 (2007).
   PubMed Web of Science ®Google Scholar
• Uchida T, Ohkusa H, Nagata Y, Hyodo T, Satoh T, Irie A. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int.97(1), 56–61 (2006).
   PubMed Web of Science ®Google Scholar
• Uchida T, Ohkusa H, Yamashita H et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int. J. Urol.13(3), 228–233 (2006).
   PubMed Web of Science ®Google Scholar
• Lee HM, Hong JH, Choi HY. High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis.9(4), 439–443 (2006).
   PubMed Web of Science ®Google Scholar
• Thuroff S, Chaussy C, Vallancien G et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J. Endourol.17(8), 673–677 (2003).
   PubMedGoogle Scholar
• Chaussy C, Thuroff S. Results and side effects of high-intensity focused ultrasound in localized prostate cancer. J. Endourol.15(4), 437–440 (2001).
   PubMed Web of Science ®Google Scholar
• Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J. Endourol.14(6), 519–528 (2000).
   PubMed Web of Science ®Google Scholar
• Maestroni U, Ziveri M, Azzolini N et al. High intensity focused ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed.79(3), 211–216 (2008).
   Google Scholar
• Challacombe BJ, Murphy DG, Zakri R, Cahill DJ. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up. BJU Int.104(2), 200–204 (2009).
   PubMed Web of Science ®Google Scholar
• Koch MO, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT. Phase I/II trial of high intensity focused ultrasound for the treatment of previously untreated localized prostate cancer. J. Urol.178(6), 2366–2370 (2007).
   PubMed Web of Science ®Google Scholar
• Ficarra V, Antoniolli SZ, Novara G et al. Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int.98(6), 1193–1198 (2006).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA280(11), 969–974 (1998).
   PubMed Web of Science ®Google Scholar
• Nguyen PL, D’Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer110(7), 1417–1428 (2007).
   PubMed Web of Science ®Google Scholar
• Chalasani V, Martinez CH, Lim D, Chin J. Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis.12(2), 124–129 (2009).
   PubMed Web of Science ®Google Scholar
• Murat FJ, Poissonnier L, Rabilloud M et al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol.55(3), 640–647 (2009).
   PubMed Web of Science ®Google Scholar
• Mallick S, Dufour A, Fouques Y, Bensadoun H. Salvage therapy using high intensity foccused ultrasound for local recurrence of prostate cancer after radiation therapy. Eur. Urol. Suppl.5(2), 132 (2006).
   Google Scholar
• Gelet A, Chapelon JY, Poissonnier L et al. Local recurrence of prostate cancer after external beam radiation: early experience of salvage therapy using high intensity focused ultrasound. Urology63(4), 625–629 (2004).
   PubMed Web of Science ®Google Scholar
• Seo SI, Jeon SS, Jo MK, Lee HM, Choi HY. Salvage high-intensity focused ultrasound (HIFU) therapy for locally recurrent prostate cancer after primary HIFU or external beam radiation therapy (EBRT). Eur. Urol. Suppl.7(3), 119–119 (2008).
   Web of Science ®Google Scholar
• Zacharakis E, Ahmed HU, Ishaq A et al. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int.102(7), 786–792 (2008).
   PubMed Web of Science ®Google Scholar
• Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J. Urol.178(4 Pt 1), 1253–1257 (2007).
   Google Scholar
• Nielsen ME, Partin AW. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev. Urol.9(2), 57–62 (2007).
   PubMedGoogle Scholar
• Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int. J. Radiat. Oncol. Biol. Phys.37(5), 1035–1041 (1997).
   PubMed Web of Science ®Google Scholar
• Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int. J. Radiat. Oncol. Biol. Phys.57(1), 11–18 (2003).
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, Hanks G, Thames H Jr et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys.65(4), 965–974 (2006).
   PubMed Web of Science ®Google Scholar
• Blana A, Brown SC, Chaussy C et al. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int.104(8), 1058–1062 (2009).
   PubMed Web of Science ®Google Scholar
• Uchida T, Illing RO, Cathcart PJ, Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate?. BJU Int.98(3), 537–539 (2006).
   PubMed Web of Science ®Google Scholar
• Rouviere O, Curiel L, Chapelon JY et al. Can color Doppler predict the uniformity of HIFU-induced prostate tissue destruction?. Prostate60(4), 289–297 (2004).
   Google Scholar
• Rouviere O, Mege-Lechevallier F, Chapelon JY et al. Evaluation of color Doppler in guiding prostate biopsy after HIFU ablation. Eur. Urol.50(3), 490–497 (2006).
   Google Scholar
• Pepe P, Patane D, Panella P, Aragona F. Does the adjunct of ecographic contrast medium Levovist improve the detection rate of prostate cancer?. Prostate Cancer Prostatic Dis.6(2), 159–162 (2003).
   Google Scholar
• Kim CK, Park BK, Lee HM, Kim SS, Kim E. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. AJR Am. J. Roentgenol.190(5), 1180–1186 (2008).
   Google Scholar
• Kirkham AP, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology246(3), 833–844 (2008).
   PubMedGoogle Scholar
• Cirillo S, Petracchini M, D’Urso L et al. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. BJU Int.102(4), 452–458 (2008).
   Google Scholar
• Rouviere O, Girouin N, Glas L et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur. Radiol. (2009) (Epub ahead of print).
   Google Scholar
• Wiart M, Curiel L, Gelet A, Lyonnet D, Chapelon JY, Rouviere O. Influence of perfusion on high-intensity focused ultrasound prostate ablation: a first-pass MRI study. Magn. Reson. Med.58(1), 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• Blana A, Rogenhofer S, Ganzer R, Wild PJ, Wieland WF, Walter B. Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer. World J. Urol.24(5), 585–590 (2006).
   PubMed Web of Science ®Google Scholar
• Liatsikos E, Bynens B, Rabenalt R, Kallidonis P, Do M, Stolzenburg JU. Treatment of patients after failed high intensity focused ultrasound and radiotherapy for localized prostate cancer: salvage laparoscopic extraperitoneal radical prostatectomy. J. Endourol.22(10), 2295–2298 (2008).
   Google Scholar
• Pasticier G, Chapet O, Badet L et al. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology72(6), 1305–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Chin JL, Ng CK, Touma NJ et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C–T3B prostate cancer. Prostate Cancer Prostatic Dis.11(1), 40–45 (2008).
   PubMed Web of Science ®Google Scholar
• Theodorescu D. Cryotherapy for prostate cancer: what we know, what we need to know. J. Urol.180(2), 437–438 (2008).
   Google Scholar
• Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J. Urol.178(3 Pt 2), S14–S19 (2007).
   Web of Science ®Google Scholar
• Nogueira L, Wang L, Fine SW et al. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology. (2009) (Epub ahead of print).
   Google Scholar
• Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J. Urol.170(6 Pt 2), S69–S75 (2003).
   Web of Science ®Google Scholar
• Cool D, Sherebrin S, Izawa J, Chin J, Fenster A. Design and evaluation of a 3D transrectal ultrasound prostate biopsy system. Med. Phys.35(10), 4695–4707 (2008).
   Google Scholar
• Ahmed H, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?. World J. Urol.26(5), 457–467 (2008).
   Google Scholar
• Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer70(9), 2313–2318 (1992).
   PubMed Web of Science ®Google Scholar
• de la Rosette JJMCH, Mouraviev V, Polascik TJ. Focal targeted therapy will be a future treatment modality for early stage prostate cancer. Eur. Urol. Suppl.8(5), 424–432 (2009).
   Google Scholar